El-Rayes B., Acosta-Rivera M., Neely J., Shen Y., Baccan C., Hsu Chiun. Nivolumab + Ipilimumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma: Results from CheckMake 040. Poster session presented
4. Thomas Yau, et al. Nivolumab (NIVO) + ipilimumab(IPI) combination therapy in patients (pts) with advanced hepatocellularcarcinoma (aHCC): Results from CheckMate -040. Abstract and Poster #4012.Presented at the Amer...
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial [published online ahead of print, 2022 Dec 13]. J Clin Oncol. 2022;JCO2200972. 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或...
What is the next step with nivolumab in this disease? In light of these results, how do you predict immuno-oncology agents will progress in this field? Just to have an idea, the other randomized clinical trials running in the second-line setting of this tumor [have] placebo arms [or] be...
In this first report of a PD-1 checkpoint inhibitor for the treatment of advanced hepatocellular carcinoma, we detail nivolumab safety and efficacy results from the dose-escalation and dose-expansion phases of CheckMate 040. Section snippets Study design and participants We did a multicentre, non-...
19 Nivolumab’s approval for HCC was based on results from the dose-escalation and -expansion cohorts of CheckMate 040 (NCT01658878), primarily in Child-Pugh A patients.3 The objective response rate (ORR) based on blinded independent central review (BICR) was 15% in patients treated with ...
Nivolumab plus ipilimumab as first-line treatment for advanced non–small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31-41. doi:10.1016/S1470-2045(16)30624-6PubMedGoogle ScholarCrossref 11. Hodi FS, Chesney...
4. Thomas Yau, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate -040. Abstract and Poster #4012. Presented at the American Society of Clinical Oncology Annual Meeting; May 31–June 4, 2019...
参考文献:Yau T, Zagonel V, Santoro A, et al. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial [published online ahead of print, 2022 Dec 13]. J Clin Oncol. 2022;JCO2200972. ...
4. Thomas Yau, et al. Nivolumab (NIVO) + ipilimumab(IPI) combination therapy in patients (pts) with advanced hepatocellularcarcinoma (aHCC): Results from CheckMate -040. Abstract and Poster #4012.Presented at the American Society of Clinical Oncology Annual Meeting; May31–June 4, 2019; Chica...